While some low molecular weight GTPases such as Ras and RhoA contribute to malignant transformation, a closely related family member, RhoB, has tumor-suppressive activity, but little is known about its regulation by oncogenes. In this study, we show that H-Ras, N-Ras, KRas, EGFR and ErbB2 but not v-Src suppress RhoB promoter transcriptional activity in NIH3T3 cells and human cancer cell lines derived from lung (A-549), pancreatic (Panc-1) and cervical (C33A) tumors. The EGFR and ErbB2 suppression of RhoB promoter activity is mediated by Ras. Furthermore, Ras suppresses basal as well as 5-fluorouracil (5-FU)-induced RhoB promoter activity and RhoB protein levels. Ectopic expression of RhoB, but not the closely related family member RhoA, antagonizes the ability of EGFR, ErbB2, H-Ras, N-Ras and K-Ras but not v-Src to transform NIH3T3 cells. Furthermore, RhoB, but not RhoA, inhibits colony formation and proliferation and induces anoikis in A-549 cells and Ras-transformed NIH3T3 cells. Finally, Rasmediated resistance to 5-FU-induced apoptosis is reversed by RhoB. These results demonstrate that RhoB expression is negatively regulated by oncogenes that are prevalent in human cancers, and that ectopic expression of RhoB antagonizes the ability of these oncogenes to induce transformation. Taken together the data suggest that certain oncogenes suppress RhoB as one of the critical steps leading to malignant transformation.
Introduction
Low molecular weight GTP/GDP binding GTPases are signal transducers that play a central role in many important cellular functions including cytoskeleton organization, proliferation, differentiation and development (Khosravi-Far and Der, 1994; Zohn et al., 1998) . Some of these small G-proteins have also been involved in pathological conditions such as malignant transformation. For example, Ras, RhoA, Rac1 and cdc42 have been implicated in oncogenesis, invasion and metastasis (Khosravi-Far and Der, 1994; Van Aelst and D'SouzaSchorey, 1997; Hall, 1998; Symons and Settleman, 2000; Pruitt and Der, 2001) . In contrast, a closely related family member, RhoB, which shares 86% amino-acid sequence identity with RhoA, has recently been shown to have tumor-suppressive activity Chen et al., 2000) . Though highly homologous RhoA and RhoB are distinct in several aspects. While RhoA is constitutively expressed, RhoB is inducible and has been characterized as an earlyresponse gene. RhoB is known to be induced by DNA damaging agents such as UV and g-irradiation, Nmethyl-N-nitrosourea and cisplatin as well as other chemicals such as methyl methansulfonate, hydrogen peroxide (H 2 O 2 ) and cycloheximide, and growth factors such as EGF and PDGF (Jahner and Hunter, 1991; Fritz et al., 1995; Fritz and Kaina, 1997) . Furthermore, unlike RhoA that has a half life of 24 h, RhoB's half-life is much shorter and is on the order of 1-2 h (Lebowitz et al., 1995) . Finally, while RhoA mediates oncogenesis, RhoB has tumor-suppressive activity, and it has been shown by us and others to inhibit tumor cell proliferation in rodent fibroblasts as well as human cancer cells Chen et al., 2000) . RhoB also inhibits oncogenic and tumor survival pathways and induces apoptosis in vitro and inhibit the growth of human tumors grown in nude mice (Chen et al., 2000) . Furthermore, targeted deletion of RhoB results in mice that are more sensitive to skin carcinogenesis (Liu et al., 2000) . Ras-transformed RhoB (À/À) fibroblasts from these mice are resistant to girradiation-, doxorubicin-and taxol-induced apoptosis (Liu et al., 2001) . Finally, RhoB expression levels have been recently shown to dramatically decrease with the aggressiveness of tumors in head, neck and brain cancer patients (Adnane et al., 2002; Forget et al., 2002) . Taken together, the data to date suggest that RhoB may play a protective role to prevent a step in oncogenesis and that oncogenes may have to downregulate RhoB as one step towards causing malignant transformation. We further reasoned that if this is an important step then ectopic expression of RhoB should antagonize oncogene transformation. To explore these possibilities, we have investigated the effects of cancer-causing genes on RhoB expression in NIH3T3 as well as human cancer cell lines. Furthermore, we have also evaluated the effects of ectopically expressed RhoB on transformation by oncogenes.
Results
Oncogenic H-Ras, N-Ras and K-Ras, EGFR and ErbB2 but not v-Src suppress RhoB promoter transcriptional activity in NIH3T3 cells and human cancer cell lines
Proteins that induce malignant transformation and those that suppress tumorigenesis most likely antagonize each other's functions. Recent evidence points to a tumor-suppressive function of the low molecular weight GTPase RhoB Chen et al., 2000) . In this paper we set out to determine whether oncogenes that are prevalent in human cancers suppress RhoB expression, and whether RhoB antagonizes the ability of these oncogenes to induce malignant transformation. To this end, we first evaluated the effects of several oncogenes on RhoB promoter transcriptional activity. NIH3T3 cells and human cancer cell lines derived from lung (A-549), pancreatic (Panc-1) and cervical (C33A) tumors were transiently transfected with pcDNA3 empty vectors or pcDNA3 constructs containing various oncogenes along with full-length RhoB promoter firefly luciferase reporter and SRE-renilla luciferase reporter as well as a b-gal reporter for controlling transfection efficiency as described under Materials and methods. Figure 1 shows that oncogenic H-Ras, N-Ras and K-Ras, EGFR and ErbB2 inhibited RhoB promoter transcriptional activity in a dose-dependent manner in NIH3T3 cells. In contrast, v-Src had little effect on RhoB promoter activity ( Figure 1 ). As expected v-Src did increase SRE promoter activity demonstrating that it is functional in these cells (Figure 1) . Furthermore, this v-Src increase of SRE promoter activity was similar to the increases seen with other oncogenes such as H-Ras, N-Ras and K-Ras as well as EGFR and ErbB2 (Figure 1 ). Furthermore, EGFR inhibited RhoB promoter as early as 12 h after transfection whereas v-Src had little effect at all time points studied (Figure 1g and h). The effects of the oncogenes on RhoB promoter activity were also determined in human cancer cell lines. Table 1 shows that as in NIH3T3 cells (Figure 1 ), all Ras isoforms, EGFR and ErbB2 but not v-Src inhibit RhoB promoter activity in A-549, Panc-1 and C33A cells. Transfection of 1 mg constructs resulted in inhibition values that ranged from 60 to 80% (Table 1) .
The ability of EGFR and ErbB2 to suppress RhoB promoter transcriptional activity requires Ras
The receptor tyrosine kinases EGFR and ErbB2 are known to activate Ras signaling (Buday and Downward, 1993; Alimandi et al., 1995; Hunter, 1997) . We, therefore, determined whether EGFR and ErbB2 require Ras for their ability to suppress RhoB promoter activity. To this end, NIH3T3 cells were transiently transfected with EGFR or ErbB2 along with RhoB promoter and SRE luciferase reporters as in Figure 1i and j. Dominant-negative N17-H-Ras or empty vector pcDNA3 constructs were also transfected as described under Materials and methods. Figure 1i and j shows that transfection with 1 mg EGFR-pcDNA3 and 1 mg ErbB2-pcDNA3 in the absence of N17-H-Ras (DN-Ras) inhibited RhoB promoter activity by 71 and 80%, respectively. However, in the presence of N17-H-Ras, EGFR and ErbB2 inhibited only slightly (22 and 18%, respectively) (Figure 1i and j) . As control we have also shown that EGFR and ErbB2 induced SRE promoter activity by 4.6-and 5.0-folds and that N17-H-Ras inhibited EGFR and ErbB2 from inducing SRE promoter activity (Figure 1j) . Thus, the ability of EGFR and ErbB2 to suppress RhoB promoter activity was hampered by dominant-negative N17-H-Ras suggesting that Ras mediates EGFR and ErbB2 suppression of RhoB expression.
The ability of the anticancer drug 5-fluorouracil (5-FU) to induce RhoB promoter activity is inhibited by H-Ras, N-Ras and K-Ras oncogenes
The results of Figure 1 demonstrate that certain oncogenes suppress basal (unstimulated) RhoB promoter activity. As RhoB is usually expressed at low levels and that its gene is inducible by physical (g-irradiation, UV) and chemical (DMS, N-methyl-N-nitrosourea, H 2 O 2 , cisplatin, taxol) agents (Fritz et al., 1995; Fritz and Kaina, 1997) , it would be important to determine whether oncogenes also suppress inducible RhoB levels. To this end, NIH3T3 cells were transiently transfected with oncogenes along with RhoB promoter and SRE luciferase reporter constructs as described under Figure 1 . The cells were then treated 24 h later with either DMSO vehicle or 5-FU (2 mM) for 12 h as described under Materials and methods. Figure 2a shows that treatment of cells with 5-FU, in the absence of oncogenes, induced RhoB promoter activity by more than four fold whereas transient transfection with HRas, N-Ras and K-Ras in the absence of 5-FU suppressed RhoB promoter activity by 73, 79 and 78%, respectively. In contrast, in the presence of HRas, N-Ras and K-Ras, 5-FU induced RhoB promoter activity by only one fold or less than one fold (Figure 2a) . Thus, the ability of 5-FU to induce RhoB promoter activity was potently inhibited by oncogenes.
H-Ras, N-Ras and K-Ras suppress the protein levels of RhoB
Figures 1 and 2a demonstrate that basal and induced RhoB promoter activities are suppressed by oncogenes. To determine whether RhoB protein levels are also affected by oncogenes, we transiently transfected NIH3T3 cells with HA-tagged oncogenes and deter-mined their effects on basal endogenous levels of RhoB. ) EGFR, (e) ErbB2, (f) and (h) v-Src) along with full-length RhoB promoter-firefly luciferase reporter and SRE-Renilla luciferase reporter for 36 h, b-gal was used as an internal control as described under Materials and methods. EGFR or ErbB2 (I and J) were also cotransfected with dominant-negative N17-H-Ras in addition to the reporter gene constructs. Cell lysates were processed for determination of RhoB and SRE promoter activity by luminescence as described in the Luciferase assay kit (Promega). The data are reported as ratios of Luci/b-gal from the cells transfected by the oncogene(s) over those from pcDNA3-transfected cells
Antagonistic interaction between RhoB and oncogenes K Jiang et al inducible, we treated NIH3T3 cells with the anticancer drug 5-FU in the absence of oncogenes and showed indeed that RhoB was induced by this agent (Figure 2b ). Figure 2a shows that the ability of 5-FU to induce RhoB promoter activity is hampered by Ras oncogenes. We next evaluated whether this also occurs at the protein level. Figure 2c shows that treatment of NIH3T3 cells with 5-FU for 36 h induced RhoB protein levels by three fold. Ectopic expression of H-Ras, N-Ras, K-Ras blocked the ability of 5-FU to induce RhoB protein levels ( Figure 2c ).
Induction of RhoB protein levels by 5-FU is blocked by HRas, N-Ras and K-Ras
Ectopic expression of RhoB, not RhoA, potently inhibits H-Ras, N-Ras and K-Ras, EGFR, ErbB2 but not v-Src transformation in NIH3T3 cells
The results described under Figures 1 and 2 demonstrate that RhoB promoter activity and RhoB protein basal and induced levels are suppressed by oncogenes. We reasoned that if some oncogenes must suppress RhoB expression as one of the required steps in their mechanism by which they transform cells, then forced expression of RhoB should block transformation induced by such oncogenes. To this end, we transfected NIH3T3 cells with pcDNA3 constructs that carry HRas, N-Ras and K-Ras, EGFR, ErbB2 or v-Src in the presence or absence of pcDNA3 constructs that contain RhoB and followed transformation by focus formation and soft agar assays as described under Materials and methods. As control, we also performed similar experiments with RhoA, a closely related family member that shares 86% amino-acid sequence identity with RhoB. Figure 3a shows that parental NIH3T3 cells or pcDNA3 empty vector-transfected cells grew many foci when transformed by oncogenic H-Ras or v-Src. Transformation by H-Ras along with RhoA increased the number of foci formed, so did the transformation by v-Src along with RhoA ( Figure 3a ). In contrast, transformation with H-Ras in the presence of RhoB resulted in much fewer foci (Figure 3a ). Table 2 shows that similar results were obtained with other forms of Ras (K-Ras and N-Ras) as well as other oncogenes such as EGFR and ErbB2. In contrast, ectopic expression of RhoB affected much less the transforming ability of v-Src, which did not suppress RhoB promoter activity (Figure 3a and Tables 1 and 2 ).
Indeed quantitation of the results shows that RhoB inhibited focus formation by H-Ras, N-Ras and K-Ras, EGFR and ErbB2 by 62, 39, 61, 56 and 59%, but inhibited v-Src transformation by only 15%. We next confirmed the ability of RhoB to antagonize oncogene transformation by soft agar assays. To this end, NIH3T3 cells were transfected with H-Ras, N-Ras , K-Ras or v-Src along with either empty pcDNA3 vector or pcDNA3 containing RhoB or RhoA and the cells plated on soft agar as described under Materials and methods. Figure 3b shows that parental NIH3T3 cells, or those transfected with either pcDNA3, RhoA or RhoB grew no colonies on soft agar. In contrast, H-Ras, N-Ras, K-Ras and v-Src-transfected cells grew many colonies ( Figure 3b and Table 3 ). While RhoA slightly enhanced, RhoB inhibited the ability of Ras, but not vSrc to transform NIH3T3 cells (Figure 3b and Table 3 ). Table 3 shows that the number of colonies formed in HRas, N-Ras and K-Ras transformed NIH3T3 were 54, 63 and 42, respectively. In the presence of RhoA these numbers were 77, 89 and 65. In contrast, in the presence of RhoB the number of soft agar colonies were 21, 26 and 18, respectively.
Ectopic expression of RhoB, but not RhoA, inhibits colony formation of human lung cancer A-549 cells Tables 2 and 3 show that forced expression of RhoB antagonizes the ability of Ras oncogenes to transform NIH3T3 cells. We next determined whether RhoB could antagonize the ability of A-549 cells (which naturally express a mutant K-Ras) to form colonies. To this end, A-549 cells were transfected with either pcDNA3 empty vector, RhoA-or RhoBcontaining pcDNA3 constructs and cultured in media containing G418 and colonies detected 3 weeks later as described under Materials and methods. Figure 3c shows that parental A-549, which did not receive pcDNA3, were sensitive to G418 and did not grow. In contrast, A-549 transfected with pcDNA3 grew numerous colonies. Furthermore, expression of RhoA did not hamper the ability of A-549 cells to grow colonies. However, expression of RhoB resulted in inhibition of A-549 colony formation (Figure 3c ). The actual number We next evaluated the ability of RhoB to interfere with the cell growth of nontransformed NIH3T3 fibroblasts, H-Ras-transformed NIH3T3 fibroblasts and the human lung cancer cell line A-549. Cells were transfected with pcDNA3 empty vector, RhoA-or RhoB-containing pcDNA3 as described above for Figure 3 , and cell numbers counted at 0, 24, 48, 72 and 96 h as described under Materials and methods. Figure 4a shows that RhoA enhanced the rate of growth of all three cell lines. In contrast, RhoB inhibited the growth rate of A-549 cells and H-Ras-transformed NIH3T3 cells (Figure 4a) . Interestingly, the growth rate of nontransformed NIH3T3 cells was not affected by RhoB (Figure 4a ).
Figures 3a and b and
Oncogenic H-Ras-mediated resistance to 5-FU-induced apoptosis is reversed by RhoB
Since 5-FU induces RhoB promoter activity and protein levels, we next determined whether RhoB also enhances the ability of 5-FU to induce apoptosis. Furthermore, we also determined whether RhoB could reverse Rasmediated resistance to 5-FU apoptosis. NIH3T3 cells or oncogenic H-Ras-transformed NIH3T3 cells were transiently transfected with pcDNA3 empty vector, H-Ras, RhoA or RhoB for 24 h and treated with DMSO vehicle or 5-FU for an additional 48 h and apoptosis analyzed by Annexin V labeling and flow cytometry as described under Materials and methods. Figure 4b shows that 5-FU induced 27-32% apoptosis in parental NIH3T3 cells and only 16-18% apoptosis in H-Ras-transformed NIH3T3 cells. Transfection with H-Ras in NIH3T3 cells partially inhibited the ability of 5-FU to induce apoptosis. RhoA had no significant effect on 5-FUinduced apoptosis. In contrast, RhoB enhanced the ability of 5-FU to induce apoptosis in both cell lines (Figure 4b ). The effect was more prominent in H-Rastransformed cells where RhoB increased the percent of apoptosis from 16 to 37% whereas in the parental cells it increased the percent of apoptosis from 28 to 39%.
RhoB, but not RhoA, induced anoikis
We next determined whether RhoB can induce anoikis in H-Ras-transformed NIH3T3 cells and A-549 cells. Transformed cells, but not nontransformed cells continue to survive when deprived from substratum attachment. We therefore transfected the H-Ras-transformed NIH3T3 cells and A-549 cells with either pcDNA3, RhoA or RhoB constructs for 36 h and trypsinized, counted and seeded these cells onto poly-HEMA-coated plates for 0, 12 and 24 h. Live cells were then counted as described under Materials and methods. Figure 4c shows that depriving A-549 cells from substratum attachment resulted in only 40% cell death over a 24 h period. However, in the presence of RhoB, over the same period of time, 78% of A-549 cells died. Thus, RhoB enhanced anoikis in A-549 cells. In contrast, RhoA protected these cells from anoikis Figure 4c ). Similarly, RhoA slightly protected from, whereas RhoB enhanced, anoikis in H-Ras-transformed NIH3T3 cells (Figure 4d ).
Discussion
In this paper, we have demonstrated that oncogenes that are found commonly mutated in human cancer such as the GTP/GDP binding GTPases K-Ras, N-Ras and HRas suppressed the expression of RhoB in NIH3T3 cells as well as several human cancer cell lines. Similarly, receptor tyrosine kinases such as EGFR and ErbB2, which are commonly overexpressed in cancers, were also very effective at suppressing RhoB expression. This is the first demonstration that oncogenes that are associated with poor prognosis and drug resistance of many human cancers downregulate the expression of RhoB, a gene that we and others have shown to have tumorsuppressive activity Chen et al., 2000) . Our results suggest that for these oncogenes to promote the progression of certain human cancers, they may have to downregulate the expression of genes with tumor-suppressive activity such as RhoB. This is consistent with recent findings that demonstrated in head and neck cancer patients that RhoB levels decreased dramatically as the tumors progressed from carcinoma in situ to highly aggressive, deeply infiltrating carcinomas (Adnane et al., 2002) . Similar results were also reported in brain cancer patients (Forget et al., 2002) . The ability of the Ras family and the ErbB family of genes to downregulate RhoB expression was selective in that the nonreceptor tyrosine kinase v-Src oncogene slightly increased RhoB promoter activity in some cell lines. This observation is consistent with other reports that showed that v-Src and v-Fps induced RhoB mRNA levels (Jahner and Hunter, 1991) . Interestingly, RhoB mRNA levels were also shown to be induced by Rac1 but inhibited by RhoA and RhoB itself (Fritz et al., 1995 , and data not shown).
Our demonstration that the downregulation of RhoB by receptor tyrosine kinases is mediated by Ras is important, since EGFR and ErbB2 are known to activate Ras as well as other Ras-independent pathways (Buday and Downward, 1993; Alimandi et al., 1995; Hunter, 1997) . As Ras is found mutated in about 30% of human cancers and EGFR and ErbB2 are found overexpressed in many cancers, RhoB levels are expected to be low in a great majority of tumors. This has been documented in head and neck cancer patients by us (Adnane et al., 2002) , and brain cancer patients by others (Forget et al., 2002) .
If the suppression of RhoB plays a pivotal role in Ras-, EGFR-and ErbB2-mediated malignant transformation, then ectopic expression of RhoB should antagonize this transformation. Here we demonstrated that ectopic expression of RhoB inhibited K-Ras-, N-Ras-, H-Ras-, EGFR-and ErbB2-but not v-Srcinduced transformation. This is important since v-Src did not suppress RhoB expression. Just as important is the fact that ectopic expression of RhoA enhanced the ability of Ras, EGFR and ErbB2 to transform NIH3T3 cells. This is consistent with previous work by KhosraviFar et al. (1995) that showed RhoA and Rac1 enhance Ras oncogenesis, invasion and metastasis. The ability of RhoA to downregulate RhoB (Fritz and Kaina, 1997 , and data not shown) may contribute at least in part to its ability to enhance Ras, EGFR and ErbB2 transformation of NIH3T3 cells. In addition to the effects of RhoB on Ras, EGFR and ErbB2 transformation of NIH3T3 cells, we have also demonstrated that ectopic expression of RhoB, but not RhoA, also induced anoikis and inhibited the ability of A-549 (which expresses mutant K-Ras) to proliferate and form foci. This is consistent with other studies in the pancreatic cancer cell line Panc-1 (Chen et al., 2000) as well as studies in MCF-7, DU145 and LoVo cancer cell lines . It is interesting to note that RhoB was found to inhibit proliferation of Rastransformed but not nontransformed NIH3T3 cells. In contrast, RhoA enhanced the growth rate of both transformed and nontransformed NIH3T3 cells.
The anticancer drug 5-FU is used clinically in cancers where Ras metastasis is prevalent such as colorectal carcinoma, and in these cancers 5-FU resistance is common. Another important finding of our investigation is that the ability of 5-FU to induce RhoB expression and apoptosis was antagonized by Ras, and most importantly that ectopic expression of RhoB sensitizes cells to 5-FU-induced apoptosis. Furthermore, the finding that ectopic expression of RhoB reverses Ras-mediated resistance to 5-FU is consistent with other studies that show that Ras-transformed RhoB (À/À) rodent fibroblasts are resistant to another commonly used anticancer drug, taxol (Liu et al., 2001) . Similar results also showed that RhoB (À/À) cells are resistant to g-irradiation (Liu et al., 2001) . However, this does not appear to be general to all anticancer drugs. For example, the growth in soft agar of Ras-transformed RhoB (À/À) rodent fibroblasts was still sensitive to farnesyltransferase inhibitors (Liu et al., 2000) . Therefore, RhoB induction by some anticancer agents may play a pivotal role in their ability to kill tumor cells, and that tumor resistance to these agents may arise, at least in part, by a mechanism involving oncogene-induced RhoB suppression.
Taken together, our results demonstrate that constitutively activated (i.e. Ras) or overexpressed (EGFR, ErbB2) oncogenes that are prevalent in many human cancers downregulate RhoB expression. This Table 2 Oncogenic H-Ras-, K-Ras-, N-Ras-, EGFR-and ErbB2-induced transformation is suppressed by RhoB (# of foci formed)
Oncogenes transfected
Genes cotransfected H-Ras K-Ras N-Ras EGFR ErbB2 v-Src NIH3T3 cells were transiently transfected with H-Ras, K-Ras and NRas, EGFR, ErbB2 or v-Src in the presence or absence of RhoA or RhoB or pcDNA3 vector control for 36 h. The cells were then cultured in DMEM containing 1.5% calf bovine serum for determination of their capability to form foci. After 4 weeks, the plates were stained and scanned 
Materials and methods

Tissue culture
NIH3T3 mouse fibroblasts cells were maintained in Dubelcco's minimum essential medium (DMEM) supplemented with 5% Antagonistic interaction between RhoB and oncogenes K Jiang et al calf serum and 100 mg/ml of penicillin/streptomycin. NIH3T3 cells stably transfected with constitutively active H-Ras61L (H-Ras/NIH3T3) were cultured in the same medium containing 400 mg/ml of geneticin (G418, Mediatech, Inc.). Human A-549, Panc-1 and C33A cells were obtained from ATCC and cultured in DMEM supplemented with 10% fetal bovine serum and penicillin/streptomycin.
Gene constructs and vectors
Constitutively active H-Ras61L, K-RasV12, N-RasV12 and dominant-negative N17-H-Ras were kind gifts from Dr Channing Der (University of North Carolina) (Quilliam et al., 1994; Khosravi-Far et al., 1995) . Wild-type RhoA and RhoB were subcloned into hemaglutinin (HA)-tagged pcDNA3 (Invitrogen). The orientation and the sequences of these genes were confirmed by DNA sequencing facilities at the H Lee Moffitt Cancer Center (Tampa, FL, USA). RhoB promoter construct pGEI was kindly provided by Dr Y Monden (Banyu Tsukuba Research, Japan) (Nakamura et al., 1996) . pCMV-b-galactosidase vector was purchased from Invitrogen. The serum response element (SRE) reporter construct and v-Src cDNA construct were kindly provided by Dr Richard Jove (Oncology program, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, USA) (Turkson et al., 1999) . Human EGFR, ErbB2 cDNA construct were kindly provided by Dr Noreen Luetteke (H. Lee Moffitt Cancer and Research Institute, Tampa, FL, USA) (Luetteke et al., 1994) .
RhoB promoter transcriptional activity assay
DNA transfection was performed with the standard lipofectamine protocol (Invitrogen). Briefly, cells were plated in 60-mm plates, pGEI plasmid was used at 2 mg per plate, whereas all the other plasmids were used at 0.1-1.0 mg per plate. After transfection the cells were grown for another 36-48 h. Cells were then washed twice with PBS and lyzed in Promega passive lysis buffer. Aliquots of the lysates were then used to measure the luciferase and b-galactosidase activities. The luciferase values were first divided by b-galactosidase values. The RhoB promoter transcriptional activity was determined by dividing the luciferase/b-Gal values from oncogenetransfected cells by those from pcDNA3-transfected cells. Renilla luciferase was used as a positive control for determining Ras and v-Src SRE activity in the same transfected cells. All the samples were performed in triplicate and the averages of three independent experiments were reported here.
Focus formation assay
NIH3T3 cells were seeded into 60-mm plates (1 Â 10 6 cell/per plate) 1 day prior to gene transfection. Cells were transfected with 0.1 mg of each Ras, EGFR, ErbB2 or v-Src expression vectors plus 0.9 mg of RhoA, RhoB cDNA or pcDNA3 vector control with lipofectamine (Invitrogen) according to manufacturer's recommendation. At 2 days after transfection the cells were seeded into 60-mm plates at a density of 2.5 Â 10 3 / per plate, and maintained in DMEM medium containing 1.5% CBS. The medium was changed every 3 days. After 3-4 weeks, the cells were washed once with PBS and once with PBS/ methanol (1 : 1), then washed with fresh anhydrous methanol and covered with crystal violet stain for 1 min at room temperature. Finally, the stain was displaced with water. The focus formation assay for A-549 cells was similarly performed as above except that following the transfection the cells were cultured in DMEM complete medium containing 400 mg/ml of geneticin (G418, Mediatech, Inc.). After 3 weeks, the cells were fixed with anhydrous methanol and stained with crystal violet; the plates were photographed. All the samples were performed in triplicate and a representative of three independent experiments was reported in the figure and averages7standard deviation reported in the table.
Anchorage-independent growth assay NIH3T3 cells were similarly transfected as above. The cells were trypsinized, and 2.5 Â 10 3 cells were suspended in triplicate in top soft agar layer (DMEM complete medium containing 0.35% agar) and seeded into 60-mm plates precoated by a 3-mm layer of lower agar (DMEM complete medium containing 0.7% agar). The cells were fed every 5 days for 5-6 weeks and finally stained with MTT (Sigma). All the experiments were performed in triplicate and a representative of three independent experiments was reported in the figure and averages7standard deviation in the table.
Western blot analysis
Whole cell lysates were prepared in a lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, 1.5 mg each of aprotinin and leupeptin per ml, 10 mM NaF, 10 mM NaPP i , 3 mM sodium vanadate and 15 mM glycerolphosphate. Lysates were incubated 30 min on ice and centrifuged at 13 000 g for 10 min at 41C prior to SDS-PAGE and Western blotting. A measure of 50 mg of lysates was loaded for each sample. RhoB protein was detected by anti-RhoB antibody (Santa Cruz). b-actin was detected as an internal loading control.
Cell proliferation
NIH3T3, H-Ras/NIH3T3 and A-549 cells were collected and examined for cell number by trypan blue exclusion and hemocytometer counting under microscope at 0, 24, 48, 72 and 96 h. All the samples were performed in triplicate and the averages of three independent experiments were reported.
Apoptosis assay
NIH3T3, H-Ras/NIH3T3 cells were collected by trypsinization, washed in wash buffer and stained with Annexin V and 7-AAD according to manufacturer's recommendation (PharMingen, San Diego, CA, USA). Data acquisition and analysis was performed by the Flow Cytometry Core Facility at the H. Lee Moffitt Cancer Center (Tampa, FL, USA). All the samples were performed in duplicate and a representative of three independent experiments were reported here.
Anoikis assay
H-Ras/NIH3T3 and A-549 cells were collected by trypsinization, washed twice with PBS and resuspended in serum-free medium containing 0.5% BSA; 5.0 Â 10 5 cells were then seeded in triplicates into 60-mm plates precoated with poly(2-hydroxyethylmethacrylate) (poly-HEMA, Sigma) according to the data sheet of the agents. After 24 h, the cellular viability was determined by trypan blue exclusion.
